Lopinavir-Ritonavir

Product NDC

0527-1947

11-digit product format

005271947

Labeler code

0527

Product ID

0527-1947_751545a0-3b8c-4486-821d-94eb6383dc52

Type

HUMAN PRESCRIPTION DRUG

Nonproprietary name

Lopinavir-Ritonavir

Dosage form

SOLUTION

Route

ORAL

Labeler

Lannett Company, Inc.

Application

ANDA207407

Marketing category

ANDA

Marketing start

2016-12-27

Marketing end

0000-00-00

Substance

LOPINAVIR; RITONAVIR

Active strength

80 mg/mL; mg/mL

Pharmacologic classes

Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Cytochrome P450 3A Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], HIV Protease Inhibitors [MoA], HIV Protease Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Protease Inhibitor [EPC], Protease Inhibitor [EPC], UDP Glucuronosyltransferases Inducers [MoA]

NDC exclude flag

No

Listing certified through

2023-12-31

Current FDA listing

Historical FDA.report record